Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Net Debt

Last Annual Value

-4.12M

3-Year CAGR

5%

5-Year CAGR

-70%

10-Year CAGR

-82%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Net Debt

NTRB · NASDAQ
CompanyNet Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-4.12M
N/AN/AN/A 
-58.27M
N/AN/AN/A
-3.50M
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
-125.55M
N/AN/AN/A
-38.79M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
-24.18M
N/AN/AN/A
-20.11M
N/AN/AN/A
2.74M
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-44.83M
N/AN/AN/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
-24.97M
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
-14.80M
N/AN/AN/A
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15